Melanotan II

What it is

Melanotan II is a synthetic peptide promoted online as an injectable or nasal tanning product. FDA enforcement records have long described it as an unapproved new drug. An online disclaimer or “research use” label does not convert a product marketed for human tanning into an approved medicine.

Risks and warning limits

The central uncertainty is not merely a list of possible side effects. It is the combination of an unapproved drug, incomplete clinical characterization, uncertain product identity, and serious published safety signals.

PepCurrent does not provide dosing, sourcing, product-authentication, or tanning advice.

What humans actually show

• Pigmentation can occur through melanocortin-receptor activity. That visible response does not establish long-term safety, cancer protection, product purity, or an acceptable benefit-risk profile.
• FDA's compounding-risk page says published case reports discuss serious events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. Case reports do not establish incidence or prove causation, but they are safety signals—not evidence of harmlessness.
• FDA also flags aggregation, peptide-related impurities, and potential immunogenicity for certain compounded routes.

FDA and U.S. status

Melanotan II is not an FDA-approved tanning drug. FDA records describe enforcement involving its marketing and sale as an unapproved injectable tanning agent, including claims that extended beyond tanning.

FDA has separately announced that a Pharmacy Compounding Advisory Committee meeting before the end of February 2027 will discuss Melanotan II for possible inclusion on the 503A Bulks List. FDA has not yet posted the exact meeting date, time, location, or materials. Advisory recommendations are non-binding. The announcement is not a vote, recommendation, final list action, drug approval, ban, or product-specific safety conclusion, and it does not change Melanotan II's current approval status.

What would change this answer

• FDA enforcement and import alerts
• The announced FDA advisory meeting: exact date, materials, voting questions, any committee recommendation, and any later final FDA action
• New human safety data with clearly identified products
• Reports involving pigmented lesions, neurologic events, or priapism
• Social claims that equate tanning response with protection from ultraviolet injury

Sources and records

• FDA compounding substances that may present significant safety risks
• FDA announcement for the planned Pharmacy Compounding Advisory Committee meeting
• FDA enforcement record describing Melanotan II as an unapproved new drug
• FDA Import Alert 66-41 — Melanotan I and II

Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.